Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascendis Pharma ( (ASND) ) has provided an update.
On March 16, 2026, Ascendis Pharma reported new two-year data from its pivotal ApproaCH trial in children with achondroplasia treated with once-weekly TransCon CNP, showing sustained gains in growth through Week 104 and further improvements in body proportionality during the second year. The results, presented at the ACMG 2026 meeting in Baltimore, also highlighted a generally favorable safety profile with mostly mild or moderate adverse events, no symptomatic hypotension, low rates of injection-site reactions, and strong trial retention, bolstering the clinical case for YUVIWEL as a long-term treatment option ahead of a key European regulatory decision later this year.
The most recent analyst rating on (ASND) stock is a Buy with a $325.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company that develops therapies using its TransCon prodrug technology platform, with a focus on rare endocrine and genetic disorders. Its portfolio includes TransCon CNP, recently approved in the U.S. as YUVIWEL to increase linear growth in pediatric patients with achondroplasia, and it is seeking additional approvals in other key markets.
Average Trading Volume: 715,328
Technical Sentiment Signal: Buy
Current Market Cap: $13.87B
Learn more about ASND stock on TipRanks’ Stock Analysis page.